Background
BS, Brigham Young University (1988)Ph.D., The University of Wisconsin (1993)Postdoctoral Research, Ohio State University (1993-1995)
Cancer Research
Our research is primarily in two areas. We have developed small-molecule mimics of antimicrobial peptides, and we are working to understand better their mechanism of antibacterial activity, optimize medical device coatings containing these mimics to prevent bacterial colonization, and optimizing compound structures for varied applications. We also work with immunostimulatory glycolipids and oligosaccharide vaccines.
Publications
Hashemi, M. M.; Rovig, J.; Bateman, J.; Holden, B. S.; Modzelewski, T.; Gueorguieva, I.; von Dyck, M.; Bracken, R.; Genberg, C.; Deng, S.; Savage, P. B. J. Antimicrob. Chemother. 2017, in press. Preclinical testing of a broad-spectrum antimicrobial endotracheal tube coated with an innate immune synthetic mimic.
Hashemi, M. M.; Rovig, J.; Weber, S.; Hilton, B.; Forouzan, M. M.; Savage, P. B. Antimicrob. Agents Chemother. 2017, 61, e00292-17. Susceptibility of colistin-resistant, Gram-negative bacteria to antimicrobial peptides and ceragenins.
Polonskaya, Z.; Deng, S.; Sarka, A.; Kain, L.; Comellas-Aragones, M.; McKay, C.; Kaczanowska, K.; Holt, M.; McBride, R.; Palomo, V.; Self, K.; Taylor, S.; Irimia, A.; Mehta, S. R.; Dan, J. M.; Brigger, M.; Crotty, S.; Schoenberger, S. P.; Paulson, J. C.; Wilson, I. A.; Savage, P. B.; Finn, M. G.; Teyton, L. J. Clin. Invest. 2017, 127, 1491-1504. Nanomolar affinity anti-glycan antibody generation is controlled by T cells.
Deng, S.; Kain, L.; Pereira, C. S.; Mata, S.; Macedo, M. F.; Bendelac, A.; Teyton, L.; Savage, P. B. Chem. Sci. 2017, 8, 2204-2208. Psychosine variants as antigens for natural killer T cells.
Kain, L.; Webb, B.; Anderson, B. L.; Deng, S.; Holt, M.; Castanzo, A.; Zhao, M.; Self, K.; Teyton, A.; Everett, C.; Kronenberg, M.; Zajonc, D. M.; Bendelac, A.; Savage, P. B. Teyton, L. Immunity 2014, 41, 543-554. The identification of the endogenous ligands of natural killer T cells reveals the existence of mammalian alpha-linked glycosylceramides.
Nitcheu, J.; Crabé, S.; Orlandini, B.; Nell, H.; Grygar, C.; Bellier, F.; Racouet, F.; Bendelac, A.; Deng, S.; Savage, P. B.; Teyton, L.; Serra, V. Vaccine2014, 32, 6138-6145. Efficacy of ABX196, a new NKT agonist, in prophylactic human vaccination.